BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 294 filers reported holding BIO-TECHNE CORP in Q4 2017. The put-call ratio across all filers is 1.23 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,607,882 | -48.4% | 23,621 | -38.2% | 0.01% | -53.8% |
| Q2 2023 | $3,117,532 | +74.9% | 38,191 | +59.0% | 0.01% | +62.5% |
| Q1 2023 | $1,782,415 | +92444.9% | 24,025 | +3.4% | 0.01% | -11.1% |
| Q4 2022 | $1,926 | +8.1% | 23,236 | +270.5% | 0.01% | 0.0% |
| Q3 2022 | $1,781 | -99.9% | 6,272 | 0.0% | 0.01% | -10.0% |
| Q2 2022 | $2,174,000 | -20.0% | 6,272 | 0.0% | 0.01% | 0.0% |
| Q1 2022 | $2,716,000 | -58.8% | 6,272 | -50.7% | 0.01% | -58.3% |
| Q4 2021 | $6,587,000 | -29.4% | 12,732 | -33.9% | 0.02% | -33.3% |
| Q3 2021 | $9,332,000 | -0.2% | 19,255 | -7.3% | 0.04% | 0.0% |
| Q2 2021 | $9,350,000 | +127.4% | 20,766 | +92.9% | 0.04% | +111.8% |
| Q1 2021 | $4,112,000 | +11.1% | 10,766 | -7.7% | 0.02% | +6.2% |
| Q4 2020 | $3,702,000 | +34.3% | 11,658 | +4.7% | 0.02% | +23.1% |
| Q3 2020 | $2,757,000 | -42.4% | 11,131 | -38.6% | 0.01% | -43.5% |
| Q2 2020 | $4,788,000 | +5.0% | 18,131 | -12.8% | 0.02% | +15.0% |
| Q4 2019 | $4,562,000 | +38.3% | 20,783 | +23.3% | 0.02% | +33.3% |
| Q3 2019 | $3,299,000 | -48.2% | 16,858 | -44.8% | 0.02% | -51.6% |
| Q2 2019 | $6,364,000 | +58.7% | 30,522 | +51.1% | 0.03% | +55.0% |
| Q1 2019 | $4,011,000 | +171.6% | 20,203 | +98.0% | 0.02% | +150.0% |
| Q4 2018 | $1,477,000 | -27.6% | 10,203 | +2.0% | 0.01% | -20.0% |
| Q3 2018 | $2,041,000 | -31.0% | 10,000 | -50.0% | 0.01% | -33.3% |
| Q2 2018 | $2,959,000 | -72.0% | 20,000 | -71.4% | 0.02% | -72.2% |
| Q1 2018 | $10,573,000 | +16.6% | 70,000 | 0.0% | 0.05% | +31.7% |
| Q4 2017 | $9,069,000 | +7.2% | 70,000 | 0.0% | 0.04% | -4.7% |
| Q3 2017 | $8,462,000 | +140.1% | 70,000 | +133.3% | 0.04% | +152.9% |
| Q2 2017 | $3,525,000 | +15.6% | 30,000 | 0.0% | 0.02% | +21.4% |
| Q1 2017 | $3,050,000 | -1.1% | 30,000 | 0.0% | 0.01% | -12.5% |
| Q4 2016 | $3,085,000 | -6.1% | 30,000 | 0.0% | 0.02% | 0.0% |
| Q3 2016 | $3,285,000 | -27.2% | 30,000 | -25.0% | 0.02% | -30.4% |
| Q2 2016 | $4,511,000 | – | 40,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |